Interference of progestins with endothelial actions of estrogens: A matter of glucocorticoid action or deprivation?

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 29, Issue 4, 2009, Pages 441-443

  Arnal, J F ^a   Gourdy, P ^a   Simoncini, T ^b  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

19 NORPREGNANE; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTRADIOL; ESTROGEN; GESTAGEN; HYDROCORTISONE; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; NOMEGESTROL ACETATE; PREGNANE DERIVATIVE; PROGESTERONE; UNCLASSIFIED DRUG; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; NITRIC OXIDE; NOS3 PROTEIN, HUMAN; PROGESTERONE DERIVATIVE; PROGESTERONE RECEPTOR;

ATHEROSCLEROSIS; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFECT; EDITORIAL; ESTROGEN ACTIVITY; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM; VASOSPASM; VENOUS THROMBOEMBOLISM; ANIMAL; CELL CULTURE; CORONARY ARTERY DISEASE; ENDOTHELIUM CELL; ENZYMOLOGY; ESTROGEN THERAPY; FEMALE; METABOLISM; NOTE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; THROMBOSIS; WOMEN'S HEALTH;

ANIMALS; CELLS, CULTURED; CORONARY DISEASE; ENDOTHELIAL CELLS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; GLUCOCORTICOIDS; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PLATELET AGGREGATION; PROGESTERONE; PROGESTERONE CONGENERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, GLUCOCORTICOID; RECEPTORS, PROGESTERONE; THROMBOSIS; WOMEN'S HEALTH;

EID: 63449128593     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.108.182337     Document Type: Editorial

References (21)

1. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335:453-461.
2. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
3. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605-613.
4. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297:1465-1477.
5. Hodgin J, Maeda N. Estrogen and mouse models of atherosclerosis. Endocrinology. 2002;143:4495-4501.
6. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science. 2005;308:1583-1587.
7. Arnal JF, Scarabin PY, Tremollieres F, Laurell H, Gourdy P. Estrogens in vascular biology and disease: where do we stand today? Curr Opin Lipidol. 2007;18:554-560.
8. Clarkson TB, Appt SE. Controversies about HRT-lessons from monkey models. Maturitas. 2005;51:64-74.
9. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701-1712.
10. Koh KK, Sakuma I. Should progestins be blamed for the failure of hormone replacement therapy to reduce cardiovascular events in randomized controlled trials? Arterioscler Thromb Vasc Biol. 2004;24:1171-1179.
11. Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med. 1997;3:324-327.
12. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003;362:428-432.
13. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Levesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115:840-845.
14. Zerr-Fouineau M, Jourdain M, Boesch C, Hecker M, Bronner C, Schini-Kerth VB. Certain progestins prevent the enhancing effect of 17{beta}-estradiol on NO-mediated inhibition of platelet aggregation by endothelial cells. Arterioscler Thromb Vasc Biol. 2009;29:586-593.
15. Simoncini T, Mannella P, Genazzani AR. Rapid estrogen actions in the cardiovascular system. Ann N Y Acad Sci. 2006;1089:424-430.
16. Simoncini T, Mannella P, Fornari L, Caruso A, Willis MY, Garibaldi S, Baldacci C, Genazzani AR. Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells. Endocrinology. 2004;145:5745-5756.
17. Wan Y, Nordeen SK. Overlapping but distinct profiles of gene expression elicited by glucocorticoids and progestins. Recent Prog Horm Res. 2003;58:199-226.
18. Barbacanne MA, Rami J, Michel JB, Philippe M, Souchard JP, Besombes JP, Bayard F, Arnal JF. Estradiol decreases endothelium-derived superoxide anion in rat aorta. Effect on NO bioactivity and peroxynitrite production. Cardiovasc Res. 1999;41:672-681.
19. Darblade B, Pendaries C, Krust A, Dupont S, Fouque MJ, Rami J, Chambon P, Bayard F, Arnal JF. Estradiol alters nitric oxide production in the mouse aorta through the alpha-, but not beta-, estrogen receptor. Circ Res. 2002;90:413-419.
20. Mendelsohn ME. Nongenomic E. R-mediated activation of endothelial nitric oxide synthase: how does it work? What does it mean? Circ Res. 2000;87:956-960.
21. Kim KH, Moriarty K, Bender JR. Vascular cell signaling by membrane estrogen receptors. Steroids. 2008;73:864-869.